Literature DB >> 33558746

Variant-proof vaccines - invest now for the next pandemic.

Dennis R Burton, Eric J Topol.   

Abstract

Keywords:  Epidemiology; Medical research; Public health; Virology

Year:  2021        PMID： 33558746     DOI： 10.1038/d41586-021-00340-4

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

Review 1.  Broadly neutralizing antiviral antibodies.

Authors:  Davide Corti; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

2.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

Authors:  Dora Pinto; Young-Jun Park; Martina Beltramello; Alexandra C Walls; M Alejandra Tortorici; Siro Bianchi; Stefano Jaconi; Katja Culap; Fabrizia Zatta; Anna De Marco; Alessia Peter; Barbara Guarino; Roberto Spreafico; Elisabetta Cameroni; James Brett Case; Rita E Chen; Colin Havenar-Daughton; Gyorgy Snell; Amalio Telenti; Herbert W Virgin; Antonio Lanzavecchia; Michael S Diamond; Katja Fink; David Veesler; Davide Corti
Journal:  Nature       Date:  2020-05-18       Impact factor: 49.962

3.  Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.

Authors:  C Garrett Rappazzo; Longping V Tse; Chengzi I Kaku; Daniel Wrapp; Mrunal Sakharkar; Deli Huang; Laura M Deveau; Thomas J Yockachonis; Andrew S Herbert; Michael B Battles; Cecilia M O'Brien; Michael E Brown; James C Geoghegan; Jonathan Belk; Linghang Peng; Linlin Yang; Yixuan Hou; Trevor D Scobey; Dennis R Burton; David Nemazee; John M Dye; James E Voss; Bronwyn M Gunn; Jason S McLellan; Ralph S Baric; Lisa E Gralinski; Laura M Walker
Journal:  Science       Date:  2021-01-25       Impact factor: 63.714

Review 4.  Recent progress in broadly neutralizing antibodies to HIV.

Authors:  Devin Sok; Dennis R Burton
Journal:  Nat Immunol       Date:  2018-10-17       Impact factor: 31.250

5.  Structural basis of broad ebolavirus neutralization by a human survivor antibody.

Authors:  Brandyn R West; Anna Z Wec; Crystal L Moyer; Marnie L Fusco; Philipp A Ilinykh; Kai Huang; Ariel S Wirchnianski; Rebekah M James; Andrew S Herbert; Sean Hui; Eileen Goodwin; Katie A Howell; Shweta Kailasan; M Javad Aman; Laura M Walker; John M Dye; Alexander Bukreyev; Kartik Chandran; Erica Ollmann Saphire
Journal:  Nat Struct Mol Biol       Date:  2019-03-04       Impact factor: 15.369

6.  Broad neutralization of SARS-related viruses by human monoclonal antibodies.

Authors:  Anna Z Wec; Daniel Wrapp; Andrew S Herbert; Daniel P Maurer; Denise Haslwanter; Mrunal Sakharkar; Rohit K Jangra; M Eugenia Dieterle; Asparouh Lilov; Deli Huang; Longping V Tse; Nicole V Johnson; Ching-Lin Hsieh; Nianshuang Wang; Juergen H Nett; Elizabeth Champney; Irina Burnina; Michael Brown; Shu Lin; Melanie Sinclair; Carl Johnson; Sarat Pudi; Robert Bortz; Ariel S Wirchnianski; Ethan Laudermilch; Catalina Florez; J Maximilian Fels; Cecilia M O'Brien; Barney S Graham; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728
  6 in total
  13 in total

1.  Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection.

Authors:  Chrispin Chaguza; Anne M Hahn; Mary E Petrone; Shuntai Zhou; David Ferguson; Mallery I Breban; Kien Pham; Mario A Peña-Hernández; Christopher Castaldi; Verity Hill; Wade Schulz; Ronald I Swanstrom; Scott C Roberts; Nathan D Grubaugh
Journal:  medRxiv       Date:  2022-07-02

2.  Computational protein modeling and the next viral pandemic.

Authors:  Oleksandr Narykov; Suhas Srinivasan; Dmitry Korkin
Journal:  Nat Methods       Date:  2021-05       Impact factor: 47.990

3.  A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.

Authors:  Panpan Zhou; Meng Yuan; Ge Song; Nathan Beutler; Namir Shaabani; Deli Huang; Wan-Ting He; Xueyong Zhu; Sean Callaghan; Peter Yong; Fabio Anzanello; Linghang Peng; James Ricketts; Mara Parren; Elijah Garcia; Stephen A Rawlings; Davey M Smith; David Nemazee; John R Teijaro; Thomas F Rogers; Ian A Wilson; Dennis R Burton; Raiees Andrabi
Journal:  bioRxiv       Date:  2022-01-21

Review 4.  Infectious disease in an era of global change.

Authors:  Rachel E Baker; Ayesha S Mahmud; Ian F Miller; Malavika Rajeev; Fidisoa Rasambainarivo; Benjamin L Rice; Saki Takahashi; Andrew J Tatem; Caroline E Wagner; Lin-Fa Wang; Amy Wesolowski; C Jessica E Metcalf
Journal:  Nat Rev Microbiol       Date:  2021-10-13       Impact factor: 78.297

5.  Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants.

Authors:  Yi-Nan Zhang; Jennifer Paynter; Cindy Sou; Tatiana Fourfouris; Ying Wang; Ciril Abraham; Timothy Ngo; Yi Zhang; Linling He; Jiang Zhu
Journal:  Sci Adv       Date:  2021-10-20       Impact factor: 14.136

6.  Common Demand vs. Limited Supply-How to Serve the Global Fight against COVID-19 through Proper Supply of COVID-19 Vaccines.

Authors:  Yiqing Su; Yanyan Li; Yanggui Liu
Journal:  Int J Environ Res Public Health       Date:  2022-01-25       Impact factor: 3.390

7.  Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses.

Authors:  Wan-Ting He; Rami Musharrafieh; Ge Song; Katharina Dueker; Longping V Tse; David R Martinez; Alexandra Schäfer; Sean Callaghan; Peter Yong; Nathan Beutler; Jonathan L Torres; Reid M Volk; Panpan Zhou; Meng Yuan; Hejun Liu; Fabio Anzanello; Tazio Capozzola; Mara Parren; Elijah Garcia; Stephen A Rawlings; Davey M Smith; Ian A Wilson; Yana Safonova; Andrew B Ward; Thomas F Rogers; Ralph S Baric; Lisa E Gralinski; Dennis R Burton; Raiees Andrabi
Journal:  bioRxiv       Date:  2022-02-08

8.  Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease.

Authors:  Panpan Zhou; Ge Song; Wan-Ting He; Nathan Beutler; Longping V Tse; David R Martinez; Alexandra Schäfer; Fabio Anzanello; Peter Yong; Linghang Peng; Katharina Dueker; Rami Musharrafieh; Sean Callaghan; Tazio Capozzola; Meng Yuan; Hejun Liu; Oliver Limbo; Mara Parren; Elijah Garcia; Stephen A Rawlings; Davey M Smith; David Nemazee; Joseph G Jardine; Ian A Wilson; Yana Safonova; Thomas F Rogers; Ralph S Baric; Lisa E Gralinski; Dennis R Burton; Raiees Andrabi
Journal:  bioRxiv       Date:  2022-03-07

9.  Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

Authors:  Martin A Redhead; C David Owen; Lennart Brewitz; Amelia H Collette; Petra Lukacik; Claire Strain-Damerell; Sean W Robinson; Patrick M Collins; Philipp Schäfer; Mark Swindells; Chris J Radoux; Iva Navratilova Hopkins; Daren Fearon; Alice Douangamath; Frank von Delft; Tika R Malla; Laura Vangeel; Thomas Vercruysse; Jan Thibaut; Pieter Leyssen; Tu-Trinh Nguyen; Mitchell Hull; Anthony Tumber; David J Hallett; Christopher J Schofield; David I Stuart; Andrew L Hopkins; Martin A Walsh
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

10.  Vaccination Schedule under Conditions of Limited Vaccine Production Rate.

Authors:  Roger Książek; Radosław Kapłan; Katarzyna Gdowska; Piotr Łebkowski
Journal:  Vaccines (Basel)       Date:  2022-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.